President Donald Trump's visit to Beijing has dominated Chinese state media, with news stories and commentary mostly striking a positive tone. Despite the grand ceremonies and glowing coverage, however, a comparison of summit readouts from the US and China suggests differences remain on key issues. (Source: Bloomberg)
President Donald Trump's visit to Beijing has dominated Chinese state media, with news stories and commentary mostly striking a positive tone. Despite the grand ceremonies and glowing coverage, however, a comparison of summit readouts from the US and China suggests differences remain on key issues. (Source: Bloomberg)
如果你想在今天的互联网上毁掉一幅世界名画，最快的方法不是物理消灭它，而是只需要给它贴上一个标签：「这是 AI 画的」。 最近，X 用户 @SHL0MS 进行了一场充满恶趣味的社会实验。他上传了一幅法国印象派大师克劳德·莫奈的《睡莲》真迹，特意打上平台的「Made with AI」标签，并配上了一段文案： 「我刚刚用 AI 生成了一张莫奈风格的图像。请尽可能详细地描述一下，这幅画作为何不如莫奈的真迹...
如果你想在今天的互联网上毁掉一幅世界名画，最快的方法不是物理消灭它，而是只需要给它贴上一个标签：「这是 AI 画的」。 最近，X 用户 @SHL0MS 进行了一场充满恶趣味的社会实验。他上传了一幅法国印象派大师克劳德·莫奈的《睡莲》真迹，特意打上平台的「Made with AI」标签，并配上了一段文案： 「我刚刚用 AI 生成了一张莫奈风格的图像。请尽可能详细地描述一下，这幅画作为何不如莫奈的真迹？」 原推文🔗 https://x.com/SHL0MS/status/2054280631807316329 面对博主的「钓鱼执法」，互联网上的 AI 艺术卫道士们瞬间闻风而动。在博主刻意强调的详细二字诱导下，评论区迅速被各种长篇大论的专业分析淹没。 比起既搞笑，又令人十分感慨的大型翻车现场，这场闹剧也向我们揭示了一个残酷的真相：在 AI 时代，真正开始产生严重幻觉的，不光只有 AI，还有人类自己。 把真莫奈画作伪装成 AI 画作后，全网的艺术专家都翻车了 截至发稿前，网友原推文更引来了 400 万网友的在线围观，并开始在各大社交平台流传开来。 这幅画本身并没有什么可疑之处。画面里是莫奈标志性的睡莲池，水面漾着零碎的光斑，笔触的边缘晕染成深深浅浅的绿，整幅画笼着一层柔和的雾气感。如果你在卢浮宫的展厅里迎面撞上它，大概率只会感叹一句「莫奈果然是莫奈」，然后掏出手机拍照。 可现在，它顶着「Made with AI」的标签挂在那里。 果不其然，网友们丝毫没有辜负博主的期待。为了证明自己拥有超越 AI 的艺术审美，评论区瞬间涌现出无数个野生列文虎克。 大家拿着显微镜，开始对这幅「AI 垃圾」进行各种细节解剖：有人信誓旦旦地指出构图的硬伤：「这一切都是一团糟，毫无空间感而言」； 有人目光如炬地抓住了色彩的破绽：「颜色是颠倒的，绿色的水面上显示的是蓝色的睡莲」； 有人痛批细节的粗糙：「缺乏质感、棱角、褶皱、缝隙、折痕、斜面和立体感，这些都是塑料艺术品的典型特征。」； 有人辣评：「画面的景深和色彩选择毫无协调性，树的倒影和睡莲混杂在一起，完全不顾空间深度和对比度，背景中睡莲和藻类的混合部分模糊不清，就像大多数 AI 作品一样。」 有人给出了看似最一针见血的评价：「你能从骨子里感觉到这幅画缺乏真正的激情，毫无灵魂的赛博废料。」 还有顶级「嘉豪」洋洋洒洒写了数百字的长文分析。 上下滑动查看...
JHVEPhoto/iStock Editorial via Getty Images Introduction It has been a while since I last rated UnitedHealth Group ( UNH ), as I gave it a buy rating back in October, and since then, the stock has been on a roller -coaster, finally settling nearly 12% higher than my last recommendation. I want to dive into the latest dynamics of the firm and understand if it is still worth buying into today’s mark...
JHVEPhoto/iStock Editorial via Getty Images Introduction It has been a while since I last rated UnitedHealth Group ( UNH ), as I gave it a buy rating back in October, and since then, the stock has been on a roller -coaster, finally settling nearly 12% higher than my last recommendation. I want to dive into the latest dynamics of the firm and understand if it is still worth buying into today’s market. Current Dynamics I’ll just quickly go through the latest earnings to have a grasp of the recent financials. First, revenue for the quarter came out to $111.72B, a beat of $2.06B and a 2% Y/Y improvement, while Q1 non-GAAP EPS came out to $7.23, a strong beat of 63 cents. Diving deeper, the medical cost ratio came out to 83.9%, a sight of relief for the street that was expecting 8.5% and a continued reduction from the year prior, as it stood at 84.8%. Though the operating cost increased to 13.8%, it reflects the incremental investments in people, processes, and technology, such as AI, to improve performance and support innovations. All of this pushed the management to raise its full-year guidance in terms of EPS from over $17.75 to over $18.25, as well as reaffirming strong cash generation plus confirming the $2B+ Q2 buyback authorization. Segment-wise, the Healthcare side saw an expansion in operating margin from 6.2% to 6.6% as the company took the strategy to trade membership for margin through aggressive repricing, such as the implementation of premium hikes across all lines of the business. This was a direct answer to the elevated medical cost and utilization trends that emerged in 2025. However, Optum was relatively mixed on a margin basis, as Rx stayed steady at 3.3%, Insight was strong at 15.3%, and Health was weak at 5.4%, with value-based care contracts still under pressure. On the membership side, it was down 1.1MM to 49.05MM as the firm exited unprofitable Medicare Advantage markets . Now, the Medicare Advantage side has been a main source of volatility for U...
Fudan University's Wu Xinbo, an adviser to China's Foreign Ministry, says President Xi Jinping's statement on Taiwan during a summit with President Donald Trump was a strong and direct message urging Washington to halt arms sales and explicitly oppose the island's independence. (Source: Bloomberg)
Fudan University's Wu Xinbo, an adviser to China's Foreign Ministry, says President Xi Jinping's statement on Taiwan during a summit with President Donald Trump was a strong and direct message urging Washington to halt arms sales and explicitly oppose the island's independence. (Source: Bloomberg)